Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume on Analyst Upgrade

Telix Pharmaceuticals Limited (NASDAQ:TLX) saw unusually-strong trading volume on Monday after Royal Bank Of Canada upgraded the stock from a hold rating to a moderate buy rating. Approximately 190,046 shares traded hands during mid-day trading, a decline of 9% from the previous session’s volume of 209,682 shares.The stock last traded at $11.49 and had previously closed at $12.59.

Other equities research analysts have also issued research reports about the company. Weiss Ratings raised Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, August 21st. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, September 15th. Citigroup reissued a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Finally, Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Monday, September 14th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Telix Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of $20.50.

Key Telix Pharmaceuticals News

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix agreed to acquire Germany’s ITM Isotope Technologies Munich in a transaction valued at up to $2.35 billion. The deal would combine Telix’s commercial radiopharmaceutical business with ITM’s radioisotope production and development capabilities, potentially creating a larger integrated oncology platform. Telix and ITM Join Forces to Create a Radiopharmaceutical Powerhouse
• Positive Sentiment: The acquisition is intended to secure long-term access to critical medical isotopes, which could reduce supply-chain constraints and support Telix’s expanding cancer-diagnostics and therapeutic pipeline. Up to $700 million of the consideration is contingent on ITM’s lead drug receiving approval and achieving specified sales targets, limiting some upfront risk. Telix to Buy Germany’s ITM for Up to $2.35 Billion
• Positive Sentiment: Royal Bank of Canada upgraded Telix from “hold” to “moderate buy,” providing a supportive analyst signal after the acquisition-related selloff. Royal Bank of Canada Upgrade
• Neutral Sentiment: Management’s research and development presentation and merger call emphasized the strategic rationale and oncology pipeline, but investors will likely seek further details on integration, financing, regulatory approvals and the timing of expected synergies. Telix Research and Development Day Transcript
• Negative Sentiment: Telix’s shares fell sharply when the transaction was announced because the $1.65 billion upfront payment—largely in Telix shares—raises dilution concerns. The acquisition’s substantial size also increases integration, financing and execution risks, explaining the market’s initially negative reaction. Telix Stock Drops Following ITM Merger Deal

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. XY Capital Ltd increased its holdings in shares of Telix Pharmaceuticals by 468.0% during the 2nd quarter. XY Capital Ltd now owns 71,291 shares of the company’s stock worth $822,000 after buying an additional 58,739 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in Telix Pharmaceuticals during the second quarter valued at about $1,731,000. Bank of America Corp DE increased its stake in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock worth $96,000 after acquiring an additional 8,423 shares during the last quarter. Lazard Asset Management LLC increased its stake in Telix Pharmaceuticals by 15.7% during the first quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the last quarter. Finally, Private Advisor Group LLC raised its holdings in shares of Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after purchasing an additional 128,070 shares during the period.

Telix Pharmaceuticals Trading Up 5.7%

The company has a quick ratio of 1.85, a current ratio of 2.01 and a debt-to-equity ratio of 1.16. The business has a fifty day moving average price of $11.32 and a 200 day moving average price of $10.41.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals for the diagnosis and treatment of cancer and other serious diseases. Its products use targeted molecules to deliver radioactive isotopes to specific tissues, supporting precision imaging and therapeutic applications.

The company’s commercial portfolio includes Illuccix, a gallium-68 radiolabeled prostate-specific membrane antigen (PSMA) imaging agent used with PET scans to help detect and manage prostate cancer.